JW Pharmaceutical develops dutasteride tablet for treatment of hair loss and benign prostatic hyperplasia

Developing dutasteride as tablets, JW Pharmaceutical is going to target the world’s KRW 1 trillion market.

JW Pharmaceutical announced on the 12^th the company succeeded in developing ‘dutasteride,’ a hair loss and benign prostatic hyperplasia treatment which originally was a soft capsule, as a tablet.

The just-developed dutasteride tablet is developed to have a body absorption rate of the sof...